The FDA cleared Gilead’s hepatitis D treatment Hepcludex (bulevirtide) nearly four years after an earlier rejection. The first decision in this approval cycle reportedly hinged on manufacturing and distribution issues, which the agency previously flagged before it would authorize the drug. With the new clearance, bulevirtide becomes an approved option for chronic hepatitis D, addressing an unmet need where limited therapies have historically constrained clinical management. The approval also signals that regulatory focus on chemistry, manufacturing, and distribution can be a gating factor even after initial clinical development progress. For Gilead and the broader liver-disease market, the action may accelerate uptake of targeted entry inhibition strategies and increase competitive pressure for next-generation hepatitis D regimens.